Floatz logo

Tenofovir Alafenamide

HIV - Human Immunodeficiency Virus

José Antonio Mata MarínSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

61 Active assets in the HIV - Human Immunodeficiency Virus cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
NEVIRAPINE ANHYDROUS
Germans Trias i Pujol Hospital
Phase 4BBB
RITONAVIR
Giovanni Di Perri
Phase 4BBB

View all 50 →

Same molecule, other indications

Tenofovir Alafenamide is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →